Pharmacological aspects of decongestants use in the treatment of patients with inflammatory diseases of the nose and paranasal sinuses in pediatric practice

Acute upper respiratory infections are common among children and are often accompanied by inflammation of the mucous membrane of the nose and paranasal sinuses. Vasoconstrictive decongestants are one of the key methods of symptomatic therapy in inflammatory ear, throat, and nose (ENT) diseases. This research explores the pharmacology of decongestants, their classification, mechanism of action, features of administration in pediatric practice, and potential side effects. The safety of drugs in terms of their chemical structure, age groups and duration of use are given special attention. The article provides a review of current guidelines on the prescription of decongestants, including international standards for the treatment of rhinitis and rhinosinusitis in children, as well as the advantages of the fixed combination of phenylephrine and dimethindene over other vasoconstrictors. Nasal dosage forms of the fixed combination of phenylephrine and dimethindene have many advantages and are considered to be the safest in pediatric practice. A comparative analysis of drugs of different pharmacological groups shows that intranasal decongestants are the most effective and virtually non-competitive drugs used in a range of inflammatory ETN diseases that are accompanied by nasal obstruction: acute rhinitis (including acute respiratory viral infections), chronic rhinitis, allergic rhinitis, acute and chronic sinusitis, acute otitis media (as an adjuvant treatment). They are indispensable in the preparation for nasal surgical interventions, swelling of the mucous membrane of the nose and paranasal sinuses after surgical interventions and in other circumstances when it is pathogenetically and symptomatically necessary to reduce the swelling of the mucous membrane of the nasal cavity and paranasal sinuses in a faster way.

1. Hay AD, Heron J, Ness A. The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study. Fam Pract. 2005;22(4):367–374. https://doi.org/10.1093/fampra/cmi035.

2. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163(4):487–494. https://doi.org/10.1001/archinte.163.4.487.

3. Баранов АА (рук.). Научно-практическая программа «Острые респираторные заболевания у детей. Лечение и профилактика». М.; 2002.

4. Chen CF, Wu KG, Hsu MC, Tang RB. Prevalence and relationship between allergic diseases and infectious diseases. J Microbiol Immunol Infect. 2001;34(1):57–62. Available at: https://pubmed.ncbi.nlm.nih.gov/11321129.

5. Bogomilsky МR. Современная оториноларингология детского возраста и ее значение для педиатрии. Pediatriya – Zhurnal im G.N. Speranskogo. 2012;91(3):143–148. (In Russ.) Available at: https://pediatriajournal.ru/archive?show=322&section=3446.

6. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. 29):1–464. https://doi.org/10.4193/Rhin20.600.

7. Tulupov DA, Karpova EP, Grabovskaya VA. Irrigation and elimination therapy in the treatment of rhinological pathology in children. Meditsinskiy Sovet. 2019;(2):76–81. (In Russ.) https://doi.org/10.21518/2079-701X-2019-2-76-81.

8. Venekamp RP, Schilder AGM, van den Hauvel M, Hay AD. Acute middle ear infection (acute otitis media) in children. BMJ. 2020;371:m4238. https://doi.org/10.1136/bmj.m4238.

9. Garaschenko TI, Boikova NE. Impaired nasal breathing and allergic rhinitis in children. Meditsinskiy Sovet. 2015;(6):72–78. (In Russ.) Available at: https://www.med-sovet.pro/jour/article/view/197/197.

10. Tengroth L, Millrud CR, Kvarnhammar AM, Kumlien Georén S, Latif L, Cardell LO. Functional effects of Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cells. PLoS ONE. 2014;9(6):e98239. https://doi.org/10.1371/journal.pone.0098239.

11. Bjerknes R, Steinsvåg SK. Inhibition of human neutrophil actin polymerization, phagocytosis and oxidative burst by components of decongestive nosedrops. Pharmacol Toxicol. 1993;73(1):41–45. https://doi.org/10.1111/j.1600-0773.1993.tb01955.x.

12. Lopatin AS, Shilenkova VV (eds.). Acute rhinosinusitis. Practical guidelines. Pharmacology and Pharmacotherapy. 2024;(Suppl.):34–53. (In Russ.) Available at: https://rhinology.ru/wp-content/uploads/2024/03/ПР_2024_compressed.pdf.

13. Abaturov AE, Agafonova EA, Petrenko LL, Babich VL. Place of nasal decongestants in the treatment of acute infectious rhinosinusitis in children. Child`s Health. 2018;23(7):691–697. (In Russ.) Available at: https://www.elibrary.ru/yqzqsd.

14. Карнеева ОВ, Юнусов АС, Гуров АВ, Абдулкеримов ХТ, Рязанцев СВ, Карпова ЕП и др. Острый синусит: клинические рекомендации. 2024. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/313_3.

15. Wang DY, Wardani RS, Singh K, Thanaviratananich S, Vicente G, Xu G et al. A survey on the management of acute rhinosinusitis among Asian physicians. Rhinology. 2011;49(3):264–271. https://doi.org/10.4193/Rhino10.169.

16. Garashchenko TI, Boikova NE, Zelenkin EM. Choice of vasoconstrictors for children with rhinosinusitis. Russian Bulletin of Perinatology and Pediatrics. 2016;61(3):124–131. (In Russ.) https://doi.org/10.21508/1027-4065-2016-61-3-92-96.

17. Krivopalov AA, Shamkina PA. Topical decongestants in otorhinolaryngologist practice. Meditsinskiy Sovet. 2020;(21):84–89. (In Russ.) https://doi.org/10.21518/2079-701X-2020-21-84-89.

18. Egorova OA. The use of decongestants in children in otorhinolaryngological practice. Pediatrics. Consilium Medicum. 2021;(2):170–176. (In Russ.) https://doi.org/10.26442/26586630.2021.2.200906.

19. Tulupov DA, Fedotov FA, Karpova EP, Grabovskaya VA. Current aspects of use of nasal vasoconstrictors and adjunctive agents in pediatric practice. Meditsinskiy Sovet. 2018;(2):114–117. (In Russ.) https://doi.org/10.21518/2079-701X-2018-2-114-117.

20. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1–12. https://doi.org/10.4193/Rhino12.000.

21. Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22–S209. https://doi.org/10.1002/alr.21695.

22. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72–e112. https://doi.org/10.1093/cid/cir1043.

23. Moldavskaja AA, Hrappo NS, Levitan BN, Petrov VV. Features of the organization of a mucous membrane and vascular systems of a cavity of a nose. Advances in Current Natural Sciences. 2006;(5):18–22. (In Russ.) Available at: https://natural-sciences.ru/ru/article/view?id=10312.

24. Drake-Lee AB, Price J. A review of the morphology of human nasal mast cells as studied by light and electron microscopy. Rhinology. 1992;30(4):229–239. Available at: https://pubmed.ncbi.nlm.nih.gov/1281923.

25. Аведисян ВЭ. Морфофункциональные особенности полости носа у детей и подростков в норме при некоторых видах патологии. АГМА; 2009. 42 с.

26. Corboz MR, Rivelli MA, Varty L, Mutter J, Cartwright M, Rizzo CA et al. Pharmacological characterization of postjunctional alpha-adrenoceptors in human nasal mucosa. Am J Rhinol. 2005;19(5):495–502. Available at: https://pubmed.ncbi.nlm.nih.gov/16270605.

27. Lacroix JS. Adrenergic and non-adrenergic mechanisms in sympathetic vascular control of the nasal mucosa. Acta Physiol Scand Suppl. 1989;581:1–63. Available at: https://pubmed.ncbi.nlm.nih.gov/2568728.

28. Zaplatnikov AL. Topical decongestants in pediatric practice: safety and clinical efficacy. Pediatriya – Zhurnal im G.N. Speranskogo. 2006;85(6):69–75. (In Russ.) Available at: https://pediatriajournal.ru/archive?show=281&section=1876.

29. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bönisch H. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010;24(6):729–739. https://doi.org/10.1111/j.1472-8206.2009.00805.x.

30. Lopatin AS. Nasal decongestants: Mechanisms of action, clinical applications and side effects. Russian Rhinology. 2007;(1):43–48. (In Russ.) Available at: https://www.elibrary.ru/hzqvff.

31. Chiba Y, Matsuo K, Sakai H, Abe K, Misawa M. Regional differences in vascular responsiveness of nasal mucosae isolated from naive guinea pigs. Auris Nasus Larynx. 2007;34(2):197–201. https://doi.org/10.1016/j.anl.2006.09.014.

32. Banashek-Meshcheriakova TV, Semyonov FV. Evaluation of the clinical efficacy of local antibacterial therapy in the treatment of acute bacterial rhinosinusitis. Terapevticheskii Arkhiv. 2020;92(12):155–159. https://doi.org/10.26442/00403660.2020.12.000834.

33. Lopatin AS. Nasal decongestants: old drugs and new formulations. Doktor. Ru. 2011;(6):17–23. (In Russ.) Available at: https://www.elibrary.ru/oytglz.

34. Ovchinnikov AYu, Edzhe MA, Khon EM. Optimization of the treatment of patients with allergic rhinitis. RMJ. 2016;(4):221–225. (In Russ.) Available at: https://www.elibrary.ru/waihgl.

35. Ovchinnikov AYu. The role of vasoconstrictors in the complex treatment of acute rhinitis symptoms. Medvestnik. 2009;(1-2):470–471. (In Russ.) Available at: https://lib.medvestnik.ru/articles/Mestososudosujivaushih-preparatov-v-kompleksnom-lechenii-simptomov-ostrogo-nasmorka.html.

36. Tarasova GD. Topic decongestants in complex therapy of upper airways diseases. Pediatric Pharmacology. 2006;3(3):54–58. (In Russ.) Available at: https://www.pedpharma.ru/jour/article/view/567.

37. Lindemann J, Leiacker R, Rettinger G, Keck T. The effect of topical xylometazoline on the mucosal temperature of the nasal septum. Am J Rhinol. 2002;16(4):229–234. Available at: https://pubmed.ncbi.nlm.nih.gov/12222949.

38. Lindemann J, Leiacker R, Wiesmiller K, Rettinger G, Keck T. Immediate effect of benzalkonium chloride in decongestant nasal spray on the human nasal mucosal temperature. Clin Otolaryngol Allied Sci. 2004;29(4):357–361. https://doi.org/10.1111/j.1365-2273.2004.00837.x.

39. Alberty Ju, Stol B. The effect of intranasal allergy medications on the human nasal cavity cilia beat frequency in vitro. Lechaschi Vrach. 2012;(2):95–98. (In Russ.) Available at: https://www.elibrary.ru/sdbudj.

40. Tulupov DA, Karpova ЕР. Possibilities of symptomatic treatment of allergic rhinitis in children. Meditsinskiy Sovet. 2019;(17):179–185. (In Russ.) https://doi.org/10.21518/2079-701X-2019-17-179-185.

41. Miroshnichenko NA, Ovchinnikov AY. Topical decongestants: myth and reality. Meditsinskiy Sovet. 2018;(12):40–43. (In Russ.) https://doi.org/10.21518/2079-701X-2018-12-40-43.

42. Marushko YuV. Experience with the use of topical decongestants in young children. Lechaschi Vrach. 2010;(11):12–27. (In Russ.) Available at: https://www.elibrary.ru/sgghex.

43. Starostina LS, Geppe NA, Farber IM, Batyreva OV, Ozerskaya IV, Malyavina US. Pediatric use of Vibrocil in acute infectious and allergic rhinitis. Uchastkovyy Pediatr. 2013;(2):14–15. (In Russ.) Available at: https://omnidoctor.ru/upload/iblock/bef/bef61fe4cdb466d7ad6fc240b8b72349.pdf.

44. Boikova NE. The modern concept of therapy for acute and chronic inflammatory diseases of the nose and paranasal sinuses in children. Meditsinskiy Sovet. 2018;(11):66–71. (In Russ.) https://doi.org/10.21518/2079-701X-2018-11-66-71.